BrainStorm Cell Therapeutics Reports Financial Results and Progress in ALS Treatment as of Q3 2026
BrainStorm Cell Therapeutics Reports Positive Developments in Q3 2026
Overview
On November 16, 2026, BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), prominent for its innovative adult stem cell therapies, announced its financial results for the third quarter ending September 30, 2026. Alongside the financial disclosures, significant corporate updates were shared, especially concerning the ongoing developments in treatments for neurodegenerative diseases, specifically ALS (Amyotrophic Lateral Sclerosis).
Leadership Statements and Vision
Chaim Lebovits, President and CEO of BrainStorm, emphasized the urgency of addressing the critical needs of ALS patients in his statements. He highlighted the preparations for launching the Phase 3b ENDURANCE study of the company's lead therapeutic, NurOwn®. This therapy has garnered attention for its potential in providing novel treatment options to those afflicted by ALS, a disease with limited current therapeutic choices.
Lebovits pointed out that with the regulatory framework becoming increasingly supportive, thanks to FDA protocols, the company continues to prepare for this essential study. Professor Peter J. Pitts, a newly appointed Executive Chairman, adds a wealth of experience as a former FDA official, instrumental for guiding the company’s strategic directions and regulatory engagements moving forward. He joined BrainStorm earlier in May 2026, marking a pivotal change in the company's leadership structure that aims to enhance operational effectiveness and capitalize on growth opportunities.
Clinical and Regulatory Progress
The Q3 report noted several milestones, including the robust foundational work being completed to initiate the Phase 3b ENDURANCE clinical study. This study is expected to involve earlier-stage ALS patients, supported by a Special Protocol Assessment agreed upon by the FDA. The regulatory body’s recent initiatives, particularly the Rare Disease Framework, show a commitment to reshaping the standards for treating such severe unmet medical needs.
A noteworthy scientific advancement highlighted in the report includes a peer-reviewed publication by the Research and Development team that documented the beneficial effects of small extracellular vesicles derived from NurOwn® cells. This significant study demonstrated decreased lung inflammation and fibrosis, while also showing improved oxygenation in preclinical models, underlining the therapeutic potential of NurOwn’s technology.
Financial Insights
Regarding financial performance for the third quarter of 2026, BrainStorm reported approximately $0.35 million in cash and cash equivalents, a notable increase from $0.24 million from the same period in 2025. Research and development expenditures stood at around $0.5 million, marking a reduction from $0.9 million in Q3 2025, while general administrative expenses were slightly lower than the previous year's figures.
The company recorded a net loss of approximately $1.7 million for Q3 2026, a decrease compared to a net loss of $2.1 million in the corresponding quarter last year. This trend indicates tightening financial management amidst significant ongoing expenses related to clinical trials and operational adjustments.
Engagement and Future Directions
BrainStorm also prioritized industry and investor engagement, with participation in key events such as the Dubai International Pharmaceuticals and Technologies Conference (DUPHAT) in August 2026. This platform allowed CEO Chaim Lebovits and Executive Chairman Peter J. Pitts to connect with regulatory bodies, potential commercial partners, and investors worldwide, focusing on strategic progression for NurOwn® and its impending trial phases.
As BrainStorm proceeds to implement its clinical strategy and enhance its leadership dynamics, the company remains committed to advancing potential therapeutic solutions that hold promise for patients suffering from ALS. With sustained regulatory support and increased engagement within the biotech community, BrainStorm is poised to navigate the complexities of bringing groundbreaking treatments from concept to reality.
Conclusion
As we closely monitor BrainStorm Cell Therapeutics' advancements, it is evident that the company's strategies and leadership are aligning to address the needs of ALS patients through innovative therapeutic developments. The financial growth and promising research findings amid evolving corporate governance suggest a hopeful trajectory for new treatment avenues in neurodegenerative disease management.